腎康注射液聯(lián)合包醛氧淀粉治療慢性腎功能衰竭的觀察

張磊

摘要：目的? 觀察腎康注射液聯(lián)合包醛氧淀粉治療慢性腎功能衰竭的臨床療效。方法? 選取2018年6月～2019年6月我院診治的112例慢性腎功能衰竭患者為研究對象，采用隨機數(shù)字表法分為對照組和觀察組，各56例。對照組采用包醛氧淀粉治療，觀察組在對照組基礎(chǔ)上聯(lián)合腎康注射液治療，比較兩組臨床治療總有效率、治療前后腎功能指標(biāo)[24h尿蛋白（24h Pro）、尿素氮（BUN）、血肌酐（Scr）]、治療后臨床癥狀評分及臨床不良反應(yīng)發(fā)生情況。結(jié)果? 觀察組臨床治療總有效率94.64%，高于對照組80.36%，差異有統(tǒng)計學(xué)意義（P<0.05）;治療后兩組24h Pro、BUN、Scr均低于治療前，且觀察組低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）;治療后觀察組惡心嘔吐、疲乏、浮腫癥狀評分均低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）;觀察組臨床不良反應(yīng)發(fā)生率（7.14%）與對照組（8.93%）比較，差異無統(tǒng)計學(xué)意義（P>0.05）。結(jié)論? 慢性腎功能衰竭采用腎康注射液聯(lián)合包醛氧淀粉治療療效確切，有助于緩解臨床癥狀、改善腎功能，且不會增加不良反應(yīng)，應(yīng)用安全可靠。

關(guān)鍵詞：腎康注射液;包醛氧淀粉;腎功能衰竭

中圖分類號：R692.5? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?文獻(xiàn)標(biāo)識碼：A? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?DOI：10.3969/j.issn.1006-1959.2020.09.050

文章編號：1006-1959（2020）09-0150-02

Observation on Treatment of Chronic Renal Failure with Shenkang Injection Combined

with Oxyamyli Tectus Aldehydum

ZHANG Lei

（Department of Nephrology，Peoples Hospital of Baodi District，Tianjin 301800，China）

Abstract：Objective? To observe the clinical effect of Shenkang injection combined with oxyamyli tectus aldehydum in the treatment of chronic renal failure.Methods? A total of 112 patients with chronic renal failure diagnosed and treated in our hospital from June 2018 to June 2019 were selected as the research object. They were divided into a control group and an observation group with a random number table method， 56 cases each. The control group was treated with oxyamyli tectus aldehydum.The observation group was treated with Shenkang injection on the basis of the control group. The total clinical treatment efficiency， renal function indexes before and after treatment were compared between the two groups[24h urine protein （24h Pro）， urea nitrogen （BUN），blood creatinine （Scr）]， clinical symptom scores and clinical adverse reactions after treatment.Results? The total effective rate of clinical treatment in the observation group was 94.64%， higher than the control group 80.36%， the difference was statistically significant（P<0.05）; 24h Pro， BUN， and Scr of the two groups after treatment were lower than before treatment， and the observation group was lower than the control The difference between the two groups was statistically significant （P<0.05）; the scores of symptoms of nausea， vomiting， fatigue and edema were lower in the observation group after treatment than the control group，the difference was statistically significant（P<0.05）;Compared with the control group （8.93%）， the incidence of clinical adverse reactions （7.14%） in the observation group was not statistically significant（P>0.05）.Conclusion? The treatment of chronic renal failure with Shenkang injection combined with oxyamyli tectus aldehydum has definite curative effect， which can help relieve clinical symptoms and improve renal function without increasing adverse reactions. It is safe and reliable.